- Home
- Companies
- Context Therapeutics Inc.
- News
- ctDNA-guided Adaptive Therapy ...
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER
Source: Context Therapeutics Inc.
Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1).
Recent preclinical studies further suggest that onapristone adds to inhibition of cell proliferation when combined with CDK4/6 inhibitors and fulvestrant (Figure 1; Unpublished).
Elevations in ctDNA can precede overt disease progression by several months in metastatic breast cancer and may represent an opportunity for proactive therapeutic intervention (2).
-
Most popular related searches
Customer comments
No comments were found for ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER. Be the first to comment!